JP2022508218A5 - - Google Patents

Info

Publication number
JP2022508218A5
JP2022508218A5 JP2021529452A JP2021529452A JP2022508218A5 JP 2022508218 A5 JP2022508218 A5 JP 2022508218A5 JP 2021529452 A JP2021529452 A JP 2021529452A JP 2021529452 A JP2021529452 A JP 2021529452A JP 2022508218 A5 JP2022508218 A5 JP 2022508218A5
Authority
JP
Japan
Application number
JP2021529452A
Other languages
Japanese (ja)
Other versions
JPWO2020112583A5 (https=
JP7398455B2 (ja
JP2022508218A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/062905 external-priority patent/WO2020112583A1/en
Publication of JP2022508218A publication Critical patent/JP2022508218A/ja
Publication of JPWO2020112583A5 publication Critical patent/JPWO2020112583A5/ja
Publication of JP2022508218A5 publication Critical patent/JP2022508218A5/ja
Application granted granted Critical
Publication of JP7398455B2 publication Critical patent/JP7398455B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021529452A 2018-11-26 2019-11-25 ピラゾロンホルミルペプチド2受容体アゴニスト Active JP7398455B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862771196P 2018-11-26 2018-11-26
US62/771,196 2018-11-26
US201962819832P 2019-03-18 2019-03-18
US62/819,832 2019-03-18
PCT/US2019/062905 WO2020112583A1 (en) 2018-11-26 2019-11-25 Pyrrolidinone derivatives as formyl peptide 2 receptor agonists

Publications (4)

Publication Number Publication Date
JP2022508218A JP2022508218A (ja) 2022-01-19
JPWO2020112583A5 JPWO2020112583A5 (https=) 2022-12-02
JP2022508218A5 true JP2022508218A5 (https=) 2022-12-02
JP7398455B2 JP7398455B2 (ja) 2023-12-14

Family

ID=68848531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021529452A Active JP7398455B2 (ja) 2018-11-26 2019-11-25 ピラゾロンホルミルペプチド2受容体アゴニスト

Country Status (7)

Country Link
US (1) US12281108B2 (https=)
EP (1) EP3887366B1 (https=)
JP (1) JP7398455B2 (https=)
KR (1) KR102877973B1 (https=)
CN (1) CN113166134B (https=)
ES (1) ES2964299T3 (https=)
WO (1) WO2020112583A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116034104B (zh) * 2020-07-09 2026-01-09 百时美施贵宝公司 氧代吡咯烷fpr2激动剂
CA3185263A1 (en) 2020-07-09 2022-01-13 James A. Johnson Pyrazolone formyl peptide 2 receptor agonists
KR20230051525A (ko) * 2020-08-12 2023-04-18 브리스톨-마이어스 스큅 컴퍼니 옥소피롤리딘 우레아 fpr2 효능제
ES2999626T3 (en) * 2020-10-09 2025-02-26 Bristol Myers Squibb Co Aminoimidazole fpr2 agonists
EP4281452A4 (en) * 2021-01-21 2024-11-06 Beijing Tiantan Hospital MODULATORS OF FPR1 AND METHODS OF USE THEREOF
WO2022155860A1 (en) * 2021-01-21 2022-07-28 Biofront Therapeutics (Beijing) Co., Ltd. Modulators of fpr1 and methods of using the same
WO2022193187A1 (en) * 2021-03-17 2022-09-22 Biofront Ltd. (Cayman) Modulators of fpr1 and methods of using same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ720508A (en) * 2013-11-28 2019-03-29 Kyorin Seiyaku Kk Urea derivative or pharmacologically acceptable salt thereof
WO2016189876A1 (en) 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
JP6746614B2 (ja) 2015-05-27 2020-08-26 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩
MX2018005756A (es) 2015-11-24 2018-08-01 Squibb Bristol Myers Co Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas.
JP6811241B2 (ja) 2015-12-10 2021-01-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ピペリジノンホルミルペプチド受容体2およびホルミルペプチド受容体1アゴニスト
TW201815762A (zh) 2016-09-21 2018-05-01 德商歌林達有限公司 經尿素及苯基取代之6員環狀胺或內醯胺
JP2020015664A (ja) * 2016-11-21 2020-01-30 宇部興産株式会社 含窒素多環式ヘテロ環誘導体
WO2018213572A1 (en) * 2017-05-17 2018-11-22 William Marsh Rice University Preparation of secondary amines with electrophilic n-linchpin reagents
KR102615099B1 (ko) 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
EP3634958B1 (en) 2017-06-09 2021-07-21 Bristol-Myers Squibb Company Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102615095B1 (ko) 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 효능제
WO2018227065A1 (en) 2017-06-09 2018-12-13 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102803660B1 (ko) 2018-03-05 2025-05-02 브리스톨-마이어스 스큅 컴퍼니 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제
EP3986903B1 (en) 2019-06-18 2023-05-10 Bristol-Myers Squibb Company Biaryl dialkyl phosphine oxide fpr2 agonists

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
JP2022508218A5 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)